Back to Search
Start Over
Fecal Metabolic Profiling of Breast Cancer Patients during Neoadjuvant Chemotherapy Reveals Potential Biomarkers
- Source :
- Molecules, Vol 26, Iss 2266, p 2266 (2021), Molecules, Molecules, MDPI, 2021, 26 (8), pp.2266. ⟨10.3390/molecules26082266⟩, Molecules, 2021, 26 (8), pp.2266. ⟨10.3390/molecules26082266⟩, Volume 26, Issue 8
- Publication Year :
- 2021
- Publisher :
- MDPI AG, 2021.
-
Abstract
- International audience; Breast cancer (BC) is the most common form of cancer among women worldwide. Despite the huge advancements in its treatment, the exact etiology of breast cancer still remains unresolved. There is an increasing interest in the role of the gut microbiome in modulating the anti-cancer therapeutic response. It seems that alteration of the microbiome-derived metabolome potentially promotes carcinogenesis. Taken together, metabolomics has arisen as a fascinating new omics field to screen promising metabolic biomarkers. In this study, fecal metabolite profiling was performed using NMR spectroscopy, to identify potential biomarker candidates that can predict response to neoadjuvant chemotherapy (NAC) for breast cancer. Metabolic profiles of feces from patients (n = 8) following chemotherapy treatment cycles were studied. Interestingly, amino acids were found to be upregulated, while lactate and fumaric acid were downregulated in patients under the second and third cycles compared with patients before treatment. Furthermore, short-chain fatty acids (SCFAs) were significantly differentiated between the studied groups. These results strongly suggest that chemotherapy treatment plays a key role in modulating the fecal metabolomic profile of BC patients. In conclusion, we demonstrate the feasibility of identifying specific fecal metabolic profiles reflecting biochemical changes that occur during the chemotherapy treatment. These data give an interesting insight that may complement and improve clinical tools for BC monitoring.
- Subjects :
- Oncology
Male
Proton Magnetic Resonance Spectroscopy
Pharmaceutical Science
Gut flora
medicine.disease_cause
Analytical Chemistry
Feces
0302 clinical medicine
MESH: Least-Squares Analysis
Drug Discovery
MESH: Metabolomics
metabolites
0303 health sciences
MESH: Proton Magnetic Resonance Spectroscopy
Principal Component Analysis
MESH: Middle Aged
biology
MESH: Feces
Discriminant Analysis
dysbiosis
Middle Aged
metabolomics
Neoadjuvant Therapy
3. Good health
Chemistry (miscellaneous)
030220 oncology & carcinogenesis
Metabolome
Molecular Medicine
Female
MESH: Biomarkers, Tumor
MESH: Metabolome
Metabolic Networks and Pathways
medicine.medical_specialty
MESH: Neoadjuvant Therapy
[SDV.CAN]Life Sciences [q-bio]/Cancer
Breast Neoplasms
Article
lcsh:QD241-441
03 medical and health sciences
Breast cancer
Metabolomics
lcsh:Organic chemistry
Internal medicine
medicine
MESH: Carbon-13 Magnetic Resonance Spectroscopy
Biomarkers, Tumor
Humans
Physical and Theoretical Chemistry
Carbon-13 Magnetic Resonance Spectroscopy
Least-Squares Analysis
MESH: Fatty Acids, Volatile
030304 developmental biology
MESH: Principal Component Analysis
MESH: Humans
gut microbiota
business.industry
breast cancer (BC)
Organic Chemistry
Cancer
MESH: Discriminant Analysis
biomarkers
MESH: ROC Curve
Omics
medicine.disease
biology.organism_classification
Fatty Acids, Volatile
MESH: Male
ROC Curve
MESH: Metabolic Networks and Pathways
[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
business
Carcinogenesis
Dysbiosis
MESH: Female
MESH: Breast Neoplasms
Subjects
Details
- Language :
- English
- ISSN :
- 14203049
- Volume :
- 26
- Issue :
- 2266
- Database :
- OpenAIRE
- Journal :
- Molecules
- Accession number :
- edsair.doi.dedup.....c1639a502db9cdd2e749db857d62119a
- Full Text :
- https://doi.org/10.3390/molecules26082266⟩